Genzyme Corp. v. ATRIUM MEDICAL CORP.

212 F. Supp. 2d 292, 2002 U.S. Dist. LEXIS 13878, 2002 WL 1603144
CourtDistrict Court, D. Delaware
DecidedJuly 19, 2002
DocketCIV.A.00-958-RRM(GMS)
StatusPublished
Cited by2 cases

This text of 212 F. Supp. 2d 292 (Genzyme Corp. v. ATRIUM MEDICAL CORP.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Genzyme Corp. v. ATRIUM MEDICAL CORP., 212 F. Supp. 2d 292, 2002 U.S. Dist. LEXIS 13878, 2002 WL 1603144 (D. Del. 2002).

Opinion

MEMORANDUM OPINION

THYNGE, United States Magistrate Judge.

Plaintiffs Genzyme Corporation, Gen-zyme Surgical Products Corporation, Donald P. Elliot, Lynn Halseth, Nicholas F. D’Antonio, and Nicholas J. D’Antonio (collectively, “Genzyme”) filed this patent infringement suit against defendant Atrium Medical Corporation on November 14, 2000. Genzyme alleges that Atrium’s “Oasis” and “Express” chest drainage devices infringe certain claims of five of its patents that relate to chest drainage devices. The five Genzyme patents-in-suit are U.S. Patent Nos. 4,889,531 (the ’531 patent); 4,544,370 (the ’370 patent); 4,715,856 (the ’856 patent); 4,747, 844 (the ’844 patent); and 4,822,346 (the ’346 patent). 1 At times, in this opinion, the court will refer to the ’531 patent as “the D’Antonio patent” and to the latter four patents collectively as “the Elliot patents.”

Presently before the court are the parties’ briefs in support of their positions as to the proper construction of the asserted claims of the patents-in-suit. This memorandum opinion is the court’s decision as to claim construction. The court will begin by briefly reviewing the technology and patents at issue. This background is drawn from the patents-in-suit and from the parties’ presentations during the May 16, 2002 claim construction hearing.

1. Background of the Technology

The patents-in-suit relate generally to “chest drainage devices,” devices which are used to remove unwanted fluids, such as blood and air, from a patient’s chest cavity. Such fluids may enter the chest during surgery or as a result of trauma. A chest drainage device, in its simplest form, is a bottle attached to a tube inserted into a patient’s chest cavity for the collection of fluids that are drained from that cavity.

A. Overview: The Elliot Patents

According to Genzyme, Deknatel, Inc., its predecessor company, introduced the first commercially successful group of chest drainage devices in 1967. 2 These early devices, called Pleur-Evacs, drained fluids and air from a patient’s chest cavity through the use of vacuum suction. In such devices, one tube is connected from the device to the patient, while another tube is connected from the device to a source of suction. Body fluids are then drained through the patient tube and into a collection chamber within the device.

An important requirement of any chest drainage device is to prevent the reverse flow of air back into the patient while it is removing air from the chest cavity. It is *297 critical to avoid air flow entering back into the patient, which can be caused when the patient takes a deep breath of air, because reverse air flow can jeopardize the patient’s breathing and create a risk of contamination.

The Pleur-Evacs prior art chest drainage devices discussed above used water-based safety features to prevent the reverse flow of fluids through the drainage device. More specifically, for this purpose, the prior art devices employ a “water seal,” a column of water that allows the forward flow of air in one direction towards the source of suction, while preventing the reverse flow of air back into the patent’s chest cavity. There are, however, several drawbacks to these “water seal” based devices. First, in order for the water seal to work effectively, water must be introduced into the device and be maintained at specific levels. Without priming the water levels before and during use, evaporation lowers the water levels within the device and thus changes the pressures at which the “fail safe” features are designed to function. This requires significant set-up time and maintenance. A second limitation is that if the device is moved, jostled, or accidentally knocked over, the resulting water spillage will cause the device to stop working, putting the patient in jeopardy.

To solve these problems caused by the use of water as a seal, the Elliot patents disclose a “waterless” (or “dry”) chest drainage device that eliminates the water seals used in traditional chest drainage devices and replaces them with a mechanical “one-way valve.” The one way valve, like the water seal that it replaces, permits vacuum pressure to evacuate air and fluid from the patient, while preventing reverse flow. This allows for accurate pressure regulation and reverse flow protection without the need for maintaining water levels. In addition to this innovation, the Elliot patents also claim additional design improvements, including a number of pressure relief and control valves and a diagnostic air leak indicator.

The ’844 and ’346 patents, which are related continuations in part, share the same specification, but have claims of differing scope. According to the specification of the patents, the invention replaces prior art water seals with a fluidless valve mechanism that provides foolproof reverse flow protection. The disclosed apparatus has multiple valves that assist in regulating pressure in the system. The valves include a check valve, a positive pressure relief valve, a control valve, and a negative pressure relief valve.

The check valve, when connected to receive air from the exhaust port of the bottle, effectively prevents back flow into the system. The type of check valve shown in the patent figures is a “flapper-type” check valve that opens in response to a relatively low pressure differential. The positive pressure valve is provided to vent any positive pressure above a predetermined value to the atmosphere, in the event that a positive pressure blows out the check valve. Similarly, a negative pressure valve, disclosed as a “popper-type” valve, is provided to respond to high negative pressures in the device by opening to admit air from the atmosphere. A control valve, disclosed as a “screw-type” valve, operates to control the pressure within the air chamber.

The apparatus described in the specification also includes a diagnostic indicator, which is depicted in Fig. 1 of the ’844 patent as transparent U-tube 62. Air removed from the patient passes through the U-tube. The U-tube, when filled with fluid, serves as an air leak detector, as well as an indicator of the inhalations and exhalations of the patient. The court has re *298 produced the portion of Figure 1 thatshows U-tube 62 below.

[[Image here]]

The ’370 and ’856 patents, which ^re also continuations in part that share the same specification, constitute improvements on the invention of the ’844 and ’346 patents. The specifications of these patents include all of the elements of that invention, but also include an intermediate diagnostic tool — U-tube 62a — that holds sterile water to detect leaks and patient breathing characteristics. The inventors, Dr. Elliot and Dr. Halseth, discovered that moving the U-tube to a downstream location provided an improved diagnostic tool that reduced the phenomenon of fluid collecting in the U-tube and backing up the patient tube.

Thus, in the normal operation of claimed chest drainage device air and fluids are evacuated from the patient’s chest cavity through a drainage tube. The air passes through the U-tube air leak indicator, which is placed either near the inlet of the device or near the outlet of the device.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

PRISM TECHNOLOGIES LLC v. VeriSign, Inc.
512 F. Supp. 2d 174 (D. Delaware, 2007)
Catalyst & Chemical Services, Inc. v. Global Ground Support
350 F. Supp. 2d 1 (District of Columbia, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
212 F. Supp. 2d 292, 2002 U.S. Dist. LEXIS 13878, 2002 WL 1603144, Counsel Stack Legal Research, https://law.counselstack.com/opinion/genzyme-corp-v-atrium-medical-corp-ded-2002.